The Latest

  • Banners marking the 2025 American Society of Clinical Oncology's annual meeting hang from the ceiling of a conference hall.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip

    ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting

    Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.

  • Multi-racial group of scientists are researching and teamworking in a laboratory.
    Image attribution tooltip
    recep-bg via Getty Images
    Image attribution tooltip
    Sponsored by Pearson

    Measuring what matters: New priorities in COA selection

    Detecting meaningful change in rare disease trials requires more than statistics—it demands the right COA. Discover why sensitivity matters and how AI is transforming trial outcomes.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    RA Capital Management is investing $30 million in Secretome Therapeutics, a company developing a new kind of cell therapy for the heart muscle weakness associated with Duchenne muscular dystrophy.

    Updated 2 hours ago
  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    Lilly dives into vaccine research with 3 biotech buyouts

    Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

  • single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Apogee eczema drugs gets Blackstone backing, heads to Phase 3

    The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA delays decision on AstraZeneca breast cancer pill

    The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.

    FDA
  • The headquarters of Eli Lilly & Co. is pictured on Aug. 1, 2019, in Indianapolis, Indiana.
    Image attribution tooltip
    "Eli Lilly Corporate Center, Indianapolis, Indiana, USA" by Momoneymoproblemz is licensed under CC BY-SA 4.0
    Image attribution tooltip
    Gene editing

    Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

    The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine

    The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.

  • A Bristol Myers Squibb employee works in one of the company's labs.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip
    Q&A // Brain drug revival

    In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

    Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Kardigan, a startup run by former MyoKardia executives, outlined an offering that would support development of heart drugs licensed from Bristol Myers, Sanofi and Ionis Pharmaceuticals.

    Updated May 27, 2026
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

    Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

  • Brain pipette
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Parkinson’s drug from Biogen, Denali comes up short

    High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.

    Updated May 22, 2026
  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    RA Capital banks $75M for a biotech SPAC

    Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers deepens AI investment with Anthropic deal

    The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.

  • Mathai Mammen, CEO, Parabilis Medicines
    Image attribution tooltip
    Permission granted by Parabilis
    Image attribution tooltip
    IPO window

    After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets

    Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.

  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin notches win in study that could expand use of top-selling medicine

    The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.

  • A person points to a CT scan of the lungs using a pen.
    Image attribution tooltip
    Vadym Plysiuk via Getty Images
    Image attribution tooltip
    Startup launches

    Oorja, run by Acceleron veterans, launches to make new fibrosis drugs

    The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly snaps up Engage to advance non-viral genetic medicines

    The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

    Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

  • People seen walking down Wall Street.
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    A migraine drugmaker heads to the public markets through reverse merger

    Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.

  • An illustration of Red and white blood cells inside a vein or artery.
    Image attribution tooltip
    SpiffyJ via Getty Images
    Image attribution tooltip

    Relay drug shows early promise against rare blood vessel diseases

    While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.

  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    Regeneron immunotherapy combo comes up short in melanoma trial

    A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

  • Corporate logos are seen outside on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    FDA approves AstraZeneca’s new kind of hypertension drug

    Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug

    The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin drug acquired in buyout misses goal in rare disease study

    Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects. 

  • Endometrial cancer cells in the uterus or cervix womb neck - closeup view 3d illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Merck ADC, licensed from China, hits mark in first big global trial

    The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.